 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Sangjin] Yuhanjang Pharmaceutical has terminated its technology transfer agreement with global pharmaceutical company Gilead Sciences for a treatment related to metabolic-associated steatotic liver disease (MASH), resulting in the return of rights associated with the therapy. This contract termination involves rights valued at approximately $785 million (about 1 trillion Korean won).
In January 2019, Gilead secured exclusive rights to develop two drug candidates targeting metabolic-associated steatotic liver disease, excluding South Korea.
With the return of rights, Yuhanjang will not have to refund the upfront payment of $15 million (around 20.2 billion Korean won) already received. The company plans to explore options for new indications and potential partners for the MASH treatment moving forward.
Alphabiz Reporter Kim SangJin(letyou@alphabiz.co.kr)
